Clinical and genetic features of the three risk groups determined by the combined application of the gene expression classifier for RFS and flow cytometric measures of MRD
| Characteristic . | Combined risk group . | Total cohort . | P (Fisher exact) . | ||
|---|---|---|---|---|---|
| Low . | Intermediate . | High . | |||
| RFS at 4 y | 87% | 62% | 29% | 61% | < .001 |
| Number of cases | 72 | 81 | 38 | 191 | |
| Age, y | |||||
| 10 or older | 56 (78%) | 40 (49%) | 29 (76%) | 125 (65%) | < .001 |
| Younger than 10 | 16 (22%) | 41 (51%) | 9 (24%) | 66 (35%) | |
| Median | 14.02 | 9.82 | 13.91 | 13.31 | |
| 5th-95th percentiles | 2.64-18.27 | 1.43-17.82 | 1.99-18.25 | 1.78-18.16 | |
| Sex | |||||
| Female | 25 | 28 | 11 | 64 | |
| Male | 47 | 53 | 27 | 127 | .83 |
| WBC, K/μL | |||||
| 50 or more | 30 | 50 | 19 | 99 | .42 |
| Less than 50 | 42 | 31 | 19 | 92 | |
| WBC count | |||||
| Median | 37.25 | 92.7 | 51.55 | 62.3 | |
| 5th-95th percentiles | 2.3-246.4 | 3-314.8 | 2.3-478 | 2.3-314.8 | |
| Race | |||||
| Hispanic and Latino | 17 | 16 | 13 | 46 | .242 |
| Others | 54 | 64 | 25 | 143 | |
| MLL | |||||
| Negative | 65 | 71 | 38 | 174 | .057 |
| Positive | 7 | 10 | 0 | 17 | |
| t(1;19)(TCF3-PBX1) | |||||
| Negative | 52 | 81 | 38 | 171 | < .001 |
| Positive | 20 | 0 | 0 | 20 | |
| CNS | |||||
| No blasts | 57 | 57 | 32 | 146 | .457 |
| Less than 5 blasts | 7 | 14 | 4 | 25 | |
| 5 or more blasts | 8 | 10 | 2 | 20 | |
| Relapse site | |||||
| Isolated CNS* | 3 | 15 | 5 | 23 | .095 |
| Marrow | 5 | 13 | 17 | 35 | |
| Characteristic . | Combined risk group . | Total cohort . | P (Fisher exact) . | ||
|---|---|---|---|---|---|
| Low . | Intermediate . | High . | |||
| RFS at 4 y | 87% | 62% | 29% | 61% | < .001 |
| Number of cases | 72 | 81 | 38 | 191 | |
| Age, y | |||||
| 10 or older | 56 (78%) | 40 (49%) | 29 (76%) | 125 (65%) | < .001 |
| Younger than 10 | 16 (22%) | 41 (51%) | 9 (24%) | 66 (35%) | |
| Median | 14.02 | 9.82 | 13.91 | 13.31 | |
| 5th-95th percentiles | 2.64-18.27 | 1.43-17.82 | 1.99-18.25 | 1.78-18.16 | |
| Sex | |||||
| Female | 25 | 28 | 11 | 64 | |
| Male | 47 | 53 | 27 | 127 | .83 |
| WBC, K/μL | |||||
| 50 or more | 30 | 50 | 19 | 99 | .42 |
| Less than 50 | 42 | 31 | 19 | 92 | |
| WBC count | |||||
| Median | 37.25 | 92.7 | 51.55 | 62.3 | |
| 5th-95th percentiles | 2.3-246.4 | 3-314.8 | 2.3-478 | 2.3-314.8 | |
| Race | |||||
| Hispanic and Latino | 17 | 16 | 13 | 46 | .242 |
| Others | 54 | 64 | 25 | 143 | |
| MLL | |||||
| Negative | 65 | 71 | 38 | 174 | .057 |
| Positive | 7 | 10 | 0 | 17 | |
| t(1;19)(TCF3-PBX1) | |||||
| Negative | 52 | 81 | 38 | 171 | < .001 |
| Positive | 20 | 0 | 0 | 20 | |
| CNS | |||||
| No blasts | 57 | 57 | 32 | 146 | .457 |
| Less than 5 blasts | 7 | 14 | 4 | 25 | |
| 5 or more blasts | 8 | 10 | 2 | 20 | |
| Relapse site | |||||
| Isolated CNS* | 3 | 15 | 5 | 23 | .095 |
| Marrow | 5 | 13 | 17 | 35 | |
Only 191 of the 207 patients in the high-risk ALL cohort had flow MRD results at end induction; hence, this table reports on 191 total patients. Flow MRD results were available on only 17 of 21 MLL and 20 of 23 t(1;19)(TCF3-PBX1) patients.
CNS indicates central nervous system.
No association was seen between patients with isolated CNS relapse and those with CNS blasts at diagnosis (χ2 test, P = .93).